1. Home
  2. PRLB vs TRVI Comparison

PRLB vs TRVI Comparison

Compare PRLB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Proto Labs Inc.

PRLB

Proto Labs Inc.

HOLD

Current Price

$72.88

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$13.39

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRLB
TRVI
Founded
1999
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
PRLB
TRVI
Price
$72.88
$13.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
11
Target Price
$53.00
$21.55
AVG Volume (30 Days)
164.1K
1.1M
Earning Date
05-01-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
33.33
31.91
EPS
0.33
N/A
Revenue
N/A
N/A
Revenue This Year
$8.56
N/A
Revenue Next Year
$6.89
N/A
P/E Ratio
$226.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.40
$5.41
52 Week High
$78.52
$16.12

Technical Indicators

Market Signals
Indicator
PRLB
TRVI
Relative Strength Index (RSI) 53.73 43.10
Support Level $47.24 $13.12
Resistance Level $73.11 $13.55
Average True Range (ATR) 2.43 0.57
MACD -0.26 -0.12
Stochastic Oscillator 41.93 15.34

Price Performance

Historical Comparison
PRLB
TRVI

About PRLB Proto Labs Inc.

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: